BACKGROUND AND OBJECTIVES: The effect of biocompatible peritoneal dialysis (PD) solutions on PD-related peritonitis is unclear. This study sought to evaluate the relationship between use of biocompatible solutions and the probability of occurrence or clinical outcomes of peritonitis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included all incident Australian patients receiving PD between January 1, 2007, and December 31, 2010, using Australia and New Zealand Dialysis and Transplant Registry data. All multicompartment PD solutions of neutral pH were categorized as biocompatible solutions. The independent predictors of peritonitis and the use of biocompatible solutions were determined by multivariable, multilevel mixed-effects Poisson and logistic regression analysis, respectively. Sensitivity analyses, including propensity score matching, were performed. RESULTS: Use of biocompatible solutions gradually declined (from 7.5% in 2007 to 4.2% in 2010), with preferential use among smaller units and among younger patients without diabetes mellitus. Treatment with biocompatible solution was associated with significantly greater overall rate of peritonitis (0.67 versus 0.47 episode per patient-year; incidence rate ratio, 1.49; 95% confidence interval [CI], 1.19 to 1.89) and with shorter time to first peritonitis (hazard ratio [HR], 1.48; 95% CI, 1.17 to 1.87), a finding replicated in propensity score-matched cohorts (HR, 1.36; 95% CI, 1.09 to 1.71). CONCLUSIONS: In an observational registry study, use of biocompatible PD solutions was associated with higher overall peritonitis rates and shorter time to first peritonitis. Further randomized studies adequately powered for a primary peritonitis outcome are warranted.
BACKGROUND AND OBJECTIVES: The effect of biocompatible peritoneal dialysis (PD) solutions on PD-related peritonitis is unclear. This study sought to evaluate the relationship between use of biocompatible solutions and the probability of occurrence or clinical outcomes of peritonitis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included all incident Australian patients receiving PD between January 1, 2007, and December 31, 2010, using Australia and New Zealand Dialysis and Transplant Registry data. All multicompartment PD solutions of neutral pH were categorized as biocompatible solutions. The independent predictors of peritonitis and the use of biocompatible solutions were determined by multivariable, multilevel mixed-effects Poisson and logistic regression analysis, respectively. Sensitivity analyses, including propensity score matching, were performed. RESULTS: Use of biocompatible solutions gradually declined (from 7.5% in 2007 to 4.2% in 2010), with preferential use among smaller units and among younger patients without diabetes mellitus. Treatment with biocompatible solution was associated with significantly greater overall rate of peritonitis (0.67 versus 0.47 episode per patient-year; incidence rate ratio, 1.49; 95% confidence interval [CI], 1.19 to 1.89) and with shorter time to first peritonitis (hazard ratio [HR], 1.48; 95% CI, 1.17 to 1.87), a finding replicated in propensity score-matched cohorts (HR, 1.36; 95% CI, 1.09 to 1.71). CONCLUSIONS: In an observational registry study, use of biocompatible PD solutions was associated with higher overall peritonitis rates and shorter time to first peritonitis. Further randomized studies adequately powered for a primary peritonitis outcome are warranted.
Authors: N Topley; R Mackenzie; M M Petersen; M J Beavis; D Williams; N Thomas; D Faict; F Peluso; G A Coles; M Davies Journal: Nephrol Dial Transplant Date: 1991 Impact factor: 5.992
Authors: B Rippe; O Simonsen; O Heimbürger; A Christensson; B Haraldsson; G Stelin; L Weiss; F D Nielsen; S Bro; M Friedberg; A Wieslander Journal: Kidney Int Date: 2001-01 Impact factor: 10.612
Authors: David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss Journal: Perit Dial Int Date: 2012 Sep-Oct Impact factor: 1.756
Authors: Siska Mortier; An S De Vriese; Rachel M McLoughlin; Nicholas Topley; Thomas P Schaub; Jutta Passlick-Deetjen; Norbert H Lameire Journal: J Am Soc Nephrol Date: 2003-05 Impact factor: 10.121
Authors: Janusz Witowski; Justyna Wisniewska; Katarzyna Korybalska; Thorsten O Bender; Andrzej Breborowicz; Gerhard M Gahl; Ulrich Frei; Jutta Passlick-Deetjen; Achim Jörres Journal: J Am Soc Nephrol Date: 2001-11 Impact factor: 10.121
Authors: Susanne Haas; Claus Peter Schmitt; Klaus Arbeiter; Klaus-Eugen Bonzel; Michel Fischbach; Ulrike John; Anne-Kathrin Pieper; Thomas Patrick Schaub; Jutta Passlick-Deetjen; Otto Mehls; Franz Schaefer Journal: J Am Soc Nephrol Date: 2003-10 Impact factor: 10.121
Authors: Gloria del Peso; José Antonio Jiménez-Heffernan; Rafael Selgas; César Remón; Marta Ossorio; Antonio Fernández-Perpén; José Antonio Sánchez-Tomero; Antonio Cirugeda; Erika de Sousa; Pilar Sandoval; Raquel Díaz; Manuel López-Cabrera; María Auxiliadora Bajo Journal: Perit Dial Int Date: 2015-10-16 Impact factor: 1.756
Authors: Tabo Sikaneta; George Wu; Mohamed Abdolell; Anita Ng; Sara Mahdavi; Anton Svendrovski; Tony Tu; Trish Mercer; Matthew Tong; Dimitrios Oreopoulos; Paul Tam Journal: Perit Dial Int Date: 2016-06-09 Impact factor: 1.756
Authors: Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Elaine M Pascoe; Margaret Clarke; Nicholas Topley Journal: BMC Nephrol Date: 2014-01-10 Impact factor: 2.388
Authors: Graham Woodrow; Stanley L Fan; Christopher Reid; Jeannette Denning; Andrew Neil Pyrah Journal: BMC Nephrol Date: 2017-11-16 Impact factor: 2.388
Authors: Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson Journal: Perit Dial Int Date: 2016-06-09 Impact factor: 1.756